Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis:Open label, randomised controlled, non-inferiority trial

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Van Herwaarden, Noortje ^a   Van Maas, Aatke Der ^a   Minten, Michiel J M ^a   Van Den Hoogen, Frank H J ^a,b   Kievit, Wietske ^b   Van Vollenhoven, Ronald F ^c   Bijlsma, Johannes W J ^d   Van Den Bemt, Bart J F ^b,e   Den Broeder, Alfons A ^a  

^a Department of Rheumatology Sint Maartenskliniek ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e SINT MAARTENSKLINIEK   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DAS28; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG ADMINISTRATION; EPIDEMIOLOGY; FOLLOW UP; FOOT; HAND; MULTICENTER STUDY; PATHOPHYSIOLOGY; RADIOGRAPHY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADALIMUMAB; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ETANERCEPT; FEMALE; FOLLOW-UP STUDIES; FOOT; HAND; HUMANS; IMMUNOGLOBULIN G; MALE; NETHERLANDS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928023549     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h1389     Document Type: Article

References (24)

1. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181:787-96.
2. Graudal N, Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010;62:2852-63.
3. Huggett B. Public biotech 2012Â-Âthe numbers. Nat Biotechnol 2013;31:697-703.
4. King S. FirstWord Lists -Pharma's 50 biggest selling drugs: AbbVie's Humira joins the $10 billion club. 7 March 2014. www. firstwordpharma.com/node/1194000#axzz3UYi8L3BI.
5. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
6. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009;68:1177-83.
7. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44.
8. Dutch medication tarifs (www.medicijnkosten.nl, accessed May 2014).
9. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
10. Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383:321-32.
11. van Herwaarden N, den Broeder AA, Jacobs WJ, van der Maas A, Bijlsma JW, van Vollenhoven RF, et al. Down titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 2014;29;9:CD010455.
12. Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082-93.
13. den Broeder AA, van Herwaarden N, van der Maas A, van den Hoogen FH, Bijlsma JW, van Vollenhoven RF, et al. Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord 2013;14:299-306.
14. van der Maas A, Lie E, Christensen R, Choy E, de Man YA, van Riel P, et al. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Ann Rheum Dis 2013;72:1800-5.
15. van der Heijde D. How to read radiographs according to the Sharp/ van der Heijde method. J Rheumatol 2000;27:261-3.
16. Welsing PM, Borm GF, van Riel PLCM. Minimal clinically important difference in radiological progression of joint damage. A definition based on patient perspective. J Rheumatol 2006;33:501-7.
17. Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002;46:913-20.
18. Navarro-Compan V, van der Heijde D, Ahmad HA, Miller CG, Wolterbeek R, Landewe R. Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC) revisited. Ann Rheum Dis 2014;73:1067-70.
19. Yoshida K, Sung YK, Kavanaugh A, Bae SC, Weinblatt ME, Kishimoto M, et al. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis 2014;73:595-9.
20. Bartlett SJ, Hewlett S, Bingham CO, III, Woodworth TG, Alten R, Pohl C, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 2012;71:1855-60.
21. Kiely PD, Brown AK, Edwards CJ, O'Reilly DT, Ostör AJ, Quinn M, et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology (Oxford) 2009;48:765-72.
22. Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, den Broeder AA, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 2012;71:845-50.
23. van Hulst LT, Hulscher ME, van Riel PL. Achieving tight control in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1729-31.
24. Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol 2014;66:775-82.